Nobuo Hirotsu Selected Research

Infections

1/2022	Comparing the cobas Influenza A/B Nucleic acid test for use on the cobas Liat System (Liat) with rapid antigen tests for clinical management of Japanese patients at the point of care.
1/2021	Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
1/2020	Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes.
1/2019	The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
1/2019	Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial.
1/2018	Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
11/2011	Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.
12/2009	Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
1/2008	A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nobuo Hirotsu Research Topics

Disease

30	Human Influenza (Influenza) 01/2023 - 06/2003
10	Fever (Fevers) 01/2023 - 05/2005
9	Infections 01/2022 - 01/2008
3	Herpesviridae Infections (Herpesvirus Infection) 01/2018 - 06/2011
1	COVID-19 01/2023
1	Pneumonia (Pneumonitis) 01/2021
1	Coinfection 01/2019
1	Reinfection 01/2013
1	Drug-Related Side Effects and Adverse Reactions 11/2011
1	Respiratory Tract Diseases (Respiratory Tract Disease) 06/2011
1	Vomiting 09/2010
1	Virus Diseases (Viral Diseases) 09/2009

Drug/Important Bio-Agent (IBA)

16	Oseltamivir (Tamiflu)FDA Link 01/2019 - 06/2003
11	Neuraminidase (Sialidase)IBA 10/2021 - 09/2009
9	Antiviral Agents (Antivirals)IBA 01/2022 - 11/2011
9	Zanamivir (Relenza)FDA Link 01/2019 - 06/2007
8	baloxavirIBA 02/2021 - 01/2018
5	AntigensIBA 01/2022 - 05/2005
5	laninamivirIBA 02/2021 - 05/2013
5	peramivirIBA 01/2019 - 09/2010
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2020
2	EndonucleasesIBA 01/2019 - 01/2018
1	Messenger RNA (mRNA)IBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Nucleic AcidsIBA 01/2022
1	VaccinesIBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	C-Reactive ProteinIBA 01/2014
1	Immunoglobulin G (IgG)IBA 01/2013
1	Immunologic Factors (Immunomodulators)IBA 01/2013
1	Clarithromycin (Biaxin)FDA LinkGeneric 01/2013
1	Immunoglobulin A (IgA)IBA 01/2013
1	benzmetanide (H 25)IBA 08/2006
1	Indicators and Reagents (Reagents)IBA 05/2005
1	Amantadine (Aman)FDA LinkGeneric 05/2005

Therapy/Procedure

7	Therapeutics 04/2012 - 08/2006
1	Aftercare (After-Treatment) 04/2012
1	Oral Administration 11/2011
1	Intravenous Infusions 11/2011
1	Intravenous Administration 09/2010